Bionano Genomics (BNGO) Liabilities and Shareholders Equity (2017 - 2026)

Bionano Genomics has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $64.8 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 17.36% year-over-year to $64.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $293.5 million (down 21.07% YoY) and the FY2025 annual result came in at $73.6 million, down 4.03% from the prior year.
• Liabilities and Shareholders Equity slipped to $64.8 million in Q1 2026 per BNGO's latest filing, from $73.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $348.2 million in Q1 2022 and troughed at $64.8 million in Q1 2026.
• A 5-year average of $181.4 million and a median of $158.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity plunged 64.24% in 2024, then dropped 4.03% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $307.5 million in 2022, then slumped by 30.28% to $214.4 million in 2023, then slumped by 64.24% to $76.7 million in 2024, then slipped by 4.03% to $73.6 million in 2025, then decreased by 11.93% to $64.8 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $64.8 million, $73.6 million, and $79.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.